Q-omics provides the consensus-scored RIBC1 profile across patient tissues and cancer cell-line models. RIBC1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RIBC1 is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, RIBC1 RNA expression shows 18,082 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight MESO, KICH, and KIRP as cancer lineages where RIBC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIBC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIBC1 survival associations across molecular data types. RIBC1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIBC1 RNA expression–survival associations across cancer types. High RIBC1 expression shows unfavorable associations in BLCA, but favorable associations in MESO, UVM, UCEC, BRCA and READ. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for RIBC1 RNA expression.
This table summarizes RIBC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 2. The strongest signals are observed in KICH for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RIBC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIBC1 shows lower tumor expression in KICH, THCA, LUAD and LUSC and higher tumor expression in COAD and LIHC. The KICH box plot shows higher RIBC1 RNA expression in normal versus tumor tissue (log2 FC = −1.890, t-test p < 0.001).
This table shows molecular features associated with RIBC1 in patient tissues and cancer cell lines. In patient samples, RIBC1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RIBC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
